Persephone Biosciences

Executive Summary

Persephone Biosciences is a San Diego-based biotechnology company founded in 2017 that leverages microbiome science and artificial intelligence to develop targeted synbiotic (probiotic/prebiotic) products. The company initially focuses on infant gut health, with a clinically validated product designed to replenish keystone bacteria missing in modern infants. Its proprietary platform integrates AI-driven discovery and machine learning to identify and optimize microbial consortia, aiming to establish a new standard of care for the human gut microbiome. Persephone's approach addresses a growing market need, as disruptions in the infant microbiome are linked to long-term health outcomes, including immune and metabolic disorders. The company has progressed from research to having a clinically validated product, suggesting strong scientific foundations and potential for commercialization. The infant gut health market is expanding, driven by rising awareness of microbiome importance and demand for evidence-based supplements. Persephone's AI platform offers a competitive edge in accelerating product development and personalization. Looking ahead, the company is well-positioned to capture value through strategic partnerships, regulatory clearances, and expansion into adjacent therapeutic areas. With a focus on data-driven innovation and a clear initial target, Persephone represents a compelling opportunity in the microbiome therapeutics space.

Upcoming Catalysts (preview)

• Q4 2026Publication of Phase 1/2 clinical trial results for lead synbiotic product in infant gut health70% success
• Q2 2027FDA GRAS (Generally Recognized as Safe) notification or regulatory submission for infant synbiotic60% success
• Q3 2026Strategic partnership or licensing deal with a major infant nutrition or pharmaceutical company50% success